| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Glioma cell proliferation is only impacted by doxycycline calcium (0.01–10 µg/mL, 4 d) at high concentrations [2]. At concentrations of 1 µg/mL and above, doxycycline calcium (0.01–10 µg/mL, 24 hours) decreases the MT-CO1 protein level in SVG cells [2]. Doxycycline calcium (100 ng/mL, 1 µg/mL; 24 hours) inhibits human cell line growth [4]. Breast cancer cells' ability to proliferate is inhibited by doxycycline calcium (0-250 μM, 72 hours) [5].
|
|---|---|
| ln Vivo |
Doxycycline calcium (oral gavage; 200 or 800 mg/kg; once daily; 3 months) lowers MMP-9 activity in untreated HT mice in a dose-dependent manner [3].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: LNT-229, G55 and U343 Glioma Cell Tested Concentrations: 0.01, 0.1, 1 or 10 µg/mL Incubation Duration: 4 days Experimental Results: Only affected at high concentrations (10 µg) Glioma cell growth/ml). Cell viability assay[2] Cell Types: SVG Cell Tested Concentrations: 0.01, 0.1, 1 or 10 µg/mL Incubation Duration: 24 hrs (hours) Experimental Results: MT-CO1 protein content diminished at concentrations of 1 µg/mL and higher. Cell proliferation assay [4] Cell Types: MCF 12A, 293T Cell Tested Concentrations: 100 ng/mL, 1 µg/mL Incubation Duration: 96 hrs (hours) Experimental Results: 1 µg/mL resulted in diminished proliferation of MCF 12A and 293T cells. Cell viability assay[5] Cell Types: MCF-7, MDA-MB-468 Cell Tested Concentrations: 0-250 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibition of breast cancer cells, MCF-7 and MCF-7 in a dose-dependent manner The IC50 values of MDA-MB-468 were 11.39 μM and 7.13 μM respectively. |
| Animal Protocol |
Animal/Disease Models: 6-month-old female heterozygous Col3a1-deficient (HT) mice [3]
Doses: 200 or 800 mg/kg Route of Administration: po (oral gavage); 200 or 800 mg/kg; one time/day; 3-month Experimental Results: MMP-9 activity diminished in a dose-dependent manner. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation A number of reviews have stated that tetracyclines are contraindicated during breastfeeding because of possible staining of infants’ dental enamel or bone deposition of tetracyclines. However, a close examination of available literature indicates that there is not likely to be harm in short-term use of doxycycline during lactation because milk levels are low and absorption by the infant is inhibited by the calcium in breastmilk. Doxycycline use in children <8 years is now considered acceptable in courses up to 21 days. As a theoretical precaution, avoid prolonged (>21 days) or repeat courses during nursing. Monitor the infant for rash and for possible effects on the gastrointestinal flora, such as diarrhea or candidiasis (thrush, diaper rash). ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
| References |
|
| Additional Infomation |
Doxycycline Calcium (internal use) can cause developmental toxicity according to state or federal government labeling requirements.
Doxycycline is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain infections. In addition, doxycycline is FDA-approved for the prevention of malaria due to Plasmodium falciparum. Many of the infections for which doxycycline is FDA-approved can be opportunistic infections (OIs) of HIV. Doxycycline Calcium is the calcium salt form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI) A synthetic tetracycline derivative with similar antimicrobial activity. See also: Doxycycline Calcium (annotation moved to). |
| Molecular Formula |
C22H20N2O8-4.2[CA+2]
|
|---|---|
| Exact Mass |
520.047
|
| CAS # |
94088-85-4
|
| Related CAS # |
Doxycycline;564-25-0;Doxycycline hydrochloride;10592-13-9;Doxycycline hyclate;24390-14-5
|
| PubChem CID |
73415789
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
685.2ºC at 760mmHg
|
| Flash Point |
368.2ºC
|
| LogP |
0.824
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
956
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4[O-])[O-])O)[O-])C(=O)N)N(C)C)[O-].[Ca+2].[Ca+2]
|
| InChi Key |
CPLUWNIKPLOTRG-QFWOMMJSSA-N
|
| InChi Code |
InChI=1S/C22H24N2O8.2Ca/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;;/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31);;/q;2*+2/t7-,10+,14+,15-,17-,22-;;/m0../s1
|
| Chemical Name |
dicalcium;(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
